Antimicrobial Effect of a Novel Chitosan Derivative and Its Synergistic Effect with Antibiotics
Zhangyong Si,Zheng Hou,Yogesh Shankar Vikhe,Kishore Reddy Venkata Thappeta,Kalisvar Marimuthu,Partha Pratim De,Oon Tek Ng,Peng Li,Yabin Zhu,Kevin Pethe,Mary B. Chan-Park
DOI: https://doi.org/10.1021/acsami.0c20881
2021-01-06
Abstract:Cationic polymers are promising antibacterial agents because bacteria have a low propensity to develop resistance against them, but they usually have low biocompatibility because of their hydrophobic moieties. Herein, we report a new biodegradable and biocompatible chitosan-derived cationic antibacterial polymer, 2,6-diamino chitosan (2,6-DAC). 2,6-DAC shows excellent broad-spectrum antimicrobial activity with minimum inhibitory concentrations (MICs) of 8-32 μg/mL against clinically relevant and multidrug-resistant (MDR) bacteria including <i>Listeria monocytogenes</i>, <i>Staphylococcus aureus</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, and <i>Acinetobacter baumannii</i>. Furthermore, 2,6-DAC shows an excellent synergistic effect with various clinically relevant antibiotics proved by decreasing the MICs of the antibiotics against MDR <i>A. baumannii</i> and methicillin-resistant <i>Staphylococcus aureus</i> to <1 μg/mL. In vivo biocompatibility of 2,6-DAC is proved by a dosage of 100 mg/kg compound via oral administration and 25 mg/kg compound via intraperitoneal injection to mice; 2,6-DAC does not cause any weight loss and any significant change in liver and kidney biomarkers or the important blood electrolytes. The combinations of 2,6-DAC together with novobiocin and rifampicin show >2.4 log<sub>10</sub> reduction of <i>A. baumannii</i> in murine intraperitoneal and lung infection models. The novel chitosan derivative, 2,6-DAC, can be utilized as a biocompatible broad-spectrum cationic antimicrobial agent alone or in synergistic combination with various antibiotics.
materials science, multidisciplinary,nanoscience & nanotechnology